Mission

Our mission is to develop and commercialize alternatives to antibiotics and offer sustainable solutions that improve animal health, production performance and food safety.

History

Founded in 2003, Prevtec Microbia is a young, innovative company that has already achieved significant milestones in the international arena.

 

2000-2003

Development of the Coliprotec® F4 vaccine by Dr. Fairbrother and Dr. Nadeau form the Université de Montréal’s Reference Laboratory for Escherichia coli (EcL)

2003

Prevtec Microbia is founded by Dr. Fairbrother and Dr. Nadeau

2005

The Coliprotec® F4 technology is transferred from Université de Montréal to Prevtec Microbia

2007

Coliprotec® F4 is approved for use in Canada

2008

Coliprotec® F4 is commercialized in Canada

2012

Prevtec Microbia signs a European Union distribution agreement with Elanco

2013

Prevtec Microbia signs a Canadian distribution agreement with Elanco

2015

Coliprotec® F4 is approved and commercialized in the European Union countries

2017

Coliprotec® F4/F18 is approved and commercialized in the European Union countries

2017

Coliprotec® F4/F18 and Coliprotec® F18 are approved and commercialized in Canada

2017

Prevtec Microbia signs a Canadian distribution agreement with Elanco for the Coliprotec® vaccine line

Business model

Prevtec Microbia has chosen a business platform that allows it to take a scientific discovery all the way through to commercialization, by teaming up with external partners and coordinating the research, development, approval and manufacturing stages while retaining the intellectual property rights associated with the discovery. This approach helps reduce the risks inherent in new product development by minimizing the company’s organizational structure. Prevtec Microbia is now replicating this process for new products, with even greater agility, speed and efficiency.

Our team
Management Team
Board of Directors

Michel Fortin has been the chief architect of Prevtec Microbia’s business and financial strategies since 2005. He has successfully closed multiple rounds of financing and negotiated intellectual property agreements, research contracts and strategic partnerships. Mr. Fortin leads Prevtec Microbia’s product development, marketing and distribution strategies for world markets.

André Halley
Chairman of the Board

André Halley

Chairman of the Board

André Halley has been a management advisor for Prevtec Microbia since 2012, particularly regarding the positioning of the company in international markets. He has over 30 years of experience as a senior executive and board member in high-tech industries. He has been the president of International Advisory Services Ltd., a strategic consulting firm for technology transfers to Asia, for the past 15 years.

Michel Fortin
Director

Michel Fortin

Director

Michel Fortin, Prevtec Microbia’s President and CEO, has been the chief architect of the company’s business and financial strategies since 2005. He has successfully closed multiple rounds of financing and negotiated intellectual property agreements, research contracts and strategic partnerships. Mr. Fortin leads Prevtec Microbia’s product development, marketing and distribution strategies for world markets.

Éric Nadeau
Vice President – Scientific Affairs

Éric Nadeau
D.M.V., M.Sc., Ph.D.

Vice President – Scientific Affairs

Éric Nadeau is the co-founder of Prevtec Microbia. He has successfully led the development and approval of veterinary vaccines in several countries, in cooperation with various partners. He is responsible for R&D and regulatory affairs. A veterinarian by training, he worked as a microbiologist researcher at the Reference Laboratory for Escherichia coli, part of Université de Montréal’s Faculty of Veterinary Medicine, where he developed various technologies now being sold or developed by Prevtec Microbia.

Éric Nadeau
Director

Éric Nadeau

Director

Éric Nadeau is Vice President, Scientific Affairs and a co-founder of Prevtec Microbia. He has successfully led the development and approval of veterinary vaccines in several countries, in cooperation with various partners. He is responsible for R&D and regulatory affairs. A veterinarian by training, he worked as a microbiologist researcher at the Reference Laboratory for Escherichia coli, part of Université de Montréal’s Faculty of Veterinary Medicine, where he developed various technologies now being sold or developed by Prevtec Microbia.

Bertrand Bolduc
Director

Bertrand Bolduc

Director

Bertrand Bolduc is the Chairman of the Board for Galenova Inc., a company specializing in the distribution of pharmaceutical products, and a partner at Gentès & Bolduc pharmacists, a pharmacy specialized in compounding. He is also Chairman of the Board for Sterinova Inc., a pharmaceutical company that produces and distributes niche pharmaceutical products for the hospital market. He has been a member of the Ordre des pharmaciens du Québec since 1990 and its president since 2014. Mr. Bolduc is certified as a director by the Institute of Corporate Directors, and is also a director of Green Shield Canada, a health insurance company.

Richard Bordeleau
Director

Richard Bordeleau

Director

Richard Bordeleau has held management positions in Ǣterna Laboratories, Atrium Innovations and BioCad Medical. In addition to being a shareholder of innovative companies, he sits on committees or boards of directors of private companies and organizations that support technology company development. Mr. Bordeleau has a degree in business administration from Laval University and completed an executive corporate strategy course at HEC Paris.

Daniel Cyr
Director

Daniel Cyr

Director

Daniel Cyr is Senior Vice President and Chief Financial Officer at Telesystem, a holding company focused on innovation, strategic partnerships and mergers and acquisitions. Mr. Cyr has over 25 years of experience in financial reporting and analysis and corporate finance, coupled with extensive expertise in mergers and acquisitions and private equity management. He is a member of the Ordre des comptables professionnels agréés du Québec.

Pierre Danis
Director

Pierre Danis

Director

Pierre Danis is Director of Administration and Finance at Délimax, the largest vertically integrated calf production company in North America. Délimax is also involved in sheep production.

Martin LeBlanc
Director

Martin LeBlanc

Director

Martin is co-founder, President and CEO of Caprion Biosciences, a leading provider of specialized proteomics and immune monitoring laboratory research services to the global pharmaceutical and biotechnology industries.  He is also a director of numerous private company and not-for-profit boards. Prior to Caprion, Martin was a management consultant for McKinsey & Company as well as co-owner and senior executive of another successful biotech venture, Advanced Bioconcept.  Martin earned his bachelor’s degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.

Jacques Perreault
Director

Jacques Perreault

Director

Jacques Perreault is Associate Vice-President at Desjardins Business Capital régional et coopératif. Over the last 20 years, he played a key role in the development and growth of technology division at the Caisse de dépôt et placement du Québec. Jacques Perreault is recognized for his broad expertise in financing technologies and for his network of local and international contacts. Sitting at a number of boards, Jacques Perreault holds a Bachelor of Business Administration – Finance degree from Université Laval and a Master of Business Administration in Economics.

Christian Roy joined Prevtec Microbia’s team in 2011. He oversees the company’s financial operations. Before joining Prevtec Microbia, he spent over 10 years in public accounting, gaining valuable experience in such areas as financial reporting, management consulting, due diligence, tax planning and compliance, and corporate finance.

Danielle Tremblay
Associate Director – Scientific Affairs

Danielle Tremblay
B.Sc., M.Sc.

Associate Director – Scientific Affairs

Danielle Tremblay joined Prevtec Microbia in 2007. As the company’s Associate Director, Scientific Affairs, she is in charge of the daily management of the teams responsible for new technology development, regulatory affairs and animal studies. Before joining Prevtec Microbia, Danielle Tremblay worked as an industrial microbiology supervisor in the agricultural industry and a microbiology expert on an R&D team.

Andre Dereu joined Prevtec in 2017 and was previously consultant for Merial (swine and cattle products). Prior to that he was senior technical manager for swine for the EuAfMe régions at Zoetis and Pfizer (2011-2015). Andre Dereu has an extensive experience of 20 years in the swine industry in Europe, Africa and the Middle East (EuAfME). He is a veterinarian by training from the University of Gent in Belgium.

 

Josef Resch
Consultant, Technical Services Germany and Austria

Josef Resch
D.M.V., Ph.D.

Consultant, Technical Services Germany and Austria

Josef Resch joined Prevtec in 2017 as a consultant. He was previously with Merial from 1985 to 2014 successively as Technical Services Manager, Product Manager Cattle Products, Head of Salesforce Large Animals and as Head of Business Unit Large Animals. In addition Josef was authorized officer (Procurist) at Merial GmbH. He has a Ph.D. in veterinarian medicine from the University of Munich.

Awards

Animal Pharm award for the Best New Product – Food Animals (2015)

Prevtec Microbia has received the 2015 Award for the Best New Product – Food Animals by the prestigious web media Animal Pharm.

The Prevtec team was thrilled to receive this global recognition of the importance of its Coliprotec® F4 vaccine for swine production. Furthermore Elanco, our distribution partner for Coliprotec® F4 in Canada and the European Union, has also received an award for the best product portfolio.

Animal Pharm reaches subscribers around the world and is a leading provider of animal health news and analysis.

Please see the link to the announcement for more details.

Prix Innovation Produit (2015)

Prevtec Microbia was the winner of the 2015 Prix Innovation Produit from the Association pour le développement de la recherche et de l’innovation du Québec (ADRIQ). The award is given to a company that recently developed and launched a clearly innovative product that gives it a net competitive advantage in its industry and its market. The new product must have a clear positive impact on the company, particularly in terms of increased sales, improved strategic positioning and profitability.

Award video: Video link

GENESIS Innovation Award (2012)

In 2012, Prevtec Microbia won the BIOQuébec GENESIS Innovation Award. Through its GENESIS Awards, BIOQuébec honours individuals and organizations for their contribution to the growth of Quebec’s biotechnology, biopharmaceutical and clinical research industry and the development of the life sciences industry in general. The GENESIS Awards seek to recognize individuals and companies for their entrepreneurship, innovation and excellence.

Genesis Transfer – Emergence Award (2008)

Prevtec Microbia won top honours in the Transfer – Emergence category at the 2008 GENESIS Awards.

Prix Innovation – Coup de cœur (2008)

Prevtec Microbia was awarded the Prix Innovation – Coup de cœur 2008 by the Association de la recherche industrielle du Québec (ADRIQ) for its innovative approach and for excellence.